You are here

  • Home
  • Archive
  • Volume 11, Issue 6
  • Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study

Article info

Article menu
Epidemiology/Health services research
Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study

Authors

  • Richeek Pradhan Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Québec, CanadaCentre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Montreal, Québec, Canada PubMed articlesGoogle scholar articles
  • Oriana H Y Yu Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Montreal, Québec, CanadaDivision of Endocrinology, Jewish General Hospital, Montreal, Québec, Canada PubMed articlesGoogle scholar articles
  • Robert W Platt Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Québec, CanadaCentre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Montreal, Québec, Canada PubMed articlesGoogle scholar articles
  • Laurent Azoulay Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Québec, CanadaCentre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Montreal, Québec, Canada PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Laurent Azoulay; laurent.azoulay{at}mcgill.ca
View Full Text

Citation

Pradhan R, Yu OHY, Platt RW, et al
Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study
BMJ Open Diabetes Research and Care 2023;11:e003550. doi: 10.1136/bmjdrc-2023-003550

Publication history

  • Received May 23, 2023
  • Accepted September 16, 2023
  • First published November 10, 2023.
Online issue publication 
November 10, 2023

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.